Back to Clinical Trials
Phase 3Recruiting

Epidemiology and Biomarker Study in Alzheimer's Disease

Sponsored by Eli Lilly and Company

About this study

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

Study AACU is a non-drug interventional study. The intervention is annual plasma P-tau217 testing. Enrollment is anticipated to be approximately 3400 participants.

Where this study is enrolling

  • Care Access - Houston

    Houston, Texas

    Call 617-843-2781

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

Who can participate

Inclusion criteria

  • ✓The participant must self-report unimpaired cognition.
  • ✓The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.

Exclusion criteria

  • ✕Have seen a doctor about memory concerns.
  • ✕Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
  • ✕Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
  • ✕Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.